Glenmark Share Price Dips 1.53% Amid New U.S. Product Launch

Glenmark Pharmaceuticals Limited informed the stock exchanges that Glenmark Pharmaceuticals Inc., USA, announced the launch of Clindamycin Phosphate Foam, 1%.

On February 12, 2025, Glenmark Pharmaceuticals share price (NSE: GLENMARK) opened at ₹1,453.90, the same as its previous close of ₹1,453.05. At 11:10 AM, the share price of Glenmark Pharmaceuticals was trading at ₹1,430.80, down by 1.53% on the NSE.

Details of Clindamycin Phosphate Foam, 1%

Clindamycin Phosphate Foam, 1% is a bioequivalent and therapeutically equivalent generic version of Evoclin® Foam, 1%, developed by Mylan Pharmaceuticals Inc.

This launch strengthens Glenmark’s dermatology portfolio in the U.S. market. According to IQVIA™ sales data, the Evoclin® Foam, 1% market, recorded annual sales of approximately $5.8 million for the 12-month period ending December 2024.

Recently, on February 10, 2025, Glenmark Pharmaceuticals and Cosmo Pharmaceuticals N.V. announced that Glenmark had received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older.

This approval marks a significant milestone in both companies’ commitment to delivering innovative and patient-focused dermatology solutions. With this launch, Glenmark strengthens its dermatology portfolio, expanding access to advanced acne treatment options in the UK pharmaceutical market.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global, research-driven pharmaceutical company operating across Branded, Generics, and OTC segments. It specialises in respiratory, dermatology, and oncology therapies. With 11 state-of-the-art manufacturing facilities across four continents, Glenmark has a strong presence in over 80 countries, delivering high-quality healthcare solutions worldwide.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.